GlassScriptPhysician profile
Ryan Martin
NPI 1790981082
$600,259.73
in general payments reported to CMS, 2019-2025
39 companies · $201K in 2025
The $201K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,355 · 2020: $1,573 · 2021: $27K · 2022: $51K · 2023: $158K · 2024: $157K · 2025: $201K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $445K · Travel and Lodging: $37K · Food and Beverage: $12K · Education: $12K · Consulting Fee: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $444,520.00 |
| Travel and Lodging | $36,529.14 |
| Food and Beverage | $12,130.52 |
| Education | $12,000.00 |
| Consulting Fee | $10,943.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $546,891.61 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Genzyme Corporation | $27,221.60 | 2019-2025 | |
| Intuitive Surgical, INC. | $18,729.85 | 2019-2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $4,447.13 | 2019-2025 | Nucala, Trelegy Ellipta |
| Veran Medical Technologies, INC. | $798.34 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $282.21 | 2019-2025 | Xywav |
| Grifols USA, LLC | $265.80 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $246.25 | 2019 | |
| Amgen INC. | $155.93 | 2022-2025 | Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $107.48 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $96.69 | 2023-2025 | Wakix |
| Sanofi-Aventis U.S. LLC | $91.99 | 2022 | |
| Inspire Medical Systems, INC. | $87.34 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.88 | 2019-2022 | |
| United Therapeutics Corporation | $67.55 | 2023-2025 | Remodulin, Orenitram, Tyvaso |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $62.09 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $52.41 | 2024-2025 | Acthar |
| Insmed, INC. | $48.62 | 2021-2025 | Arikayce |
| Resmed Corp | $48.15 | 2025 | |
| Boston Scientific Corporation | $42.88 | 2021-2025 | Ams 700 |
| Pulmonx Corporation | $40.26 | 2022 | |
| Tactile Systems Technology INC | $35.07 | 2025 | Nimbl, Flexitouch Plus |
| Astellas Pharma US INC | $33.77 | 2023-2024 | Cresemba |
| Avadel Cns Pharmaceuticals, LLC | $29.30 | 2023-2024 | Lumryz |
| Merck Sharp & Dohme LLC | $29.13 | 2019-2023 | |
| Philips North America LLC | $27.12 | 2022-2025 | Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $26.64 | 2019 | |
| Baxter Healthcare | $26.37 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $23.95 | 2025 | Smartvest |
| Circassia INC. | $23.55 | 2019-2020 | |
| Sanofi Pasteur INC. | $20.07 | 2023 | |
| Liquidia Technologies, INC. | $19.37 | 2025 | Yutrepia |
| Bayer Healthcare Pharmaceuticals INC. | $17.55 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.40 | 2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $15.03 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $14.97 | 2024 | |
| Abbvie INC. | $14.22 | 2022 | |
| Genentech USA, INC. | $12.22 | 2019 | |
| Ambu INC. | $5.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.